In cancer, the FOXO family of transcription factors functions as tumor suppressors and is directly inactivated by oncogenic signaling through the PI3K/AKT pathway. Now, Skykes et al. (2011) identify a paradoxical requirement for FOXOs in the maintenance of leukemia-initiating cells.
The PI3K/AKT/mTOR pathway regulates proliferation, growth, survival, and a cell's response to hypoxia and energy depletion. Activation of this pathway is observed in the majority of cancers, including 50% of human acute myeloid leukemias (AML) (Martelli et al., 2010) . The serine/threonine protein kinases AKT and mTOR play central roles in this pathway by controlling the activity of a large number of downstream targets, including the Forkhead Box-containing transcriptional factors FOXO1, FOXO3, and FOXO4 (referred to collectively as FOXOs) (Figure 1 ). The FOXO family controls a transcriptional network that induces quiescence, protection from oxidative stress, and, in some cells, apoptosis (Fu and Tindall, 2008) .
The PI3K/AKT/mTOR pathway negatively regulates the activity of the FOXOs through AKT-mediated phosphorylation, which results in nuclear exclusion and inhibition of transcriptional activity (Figure 1) . Moreover, the FOXOs were initially identified as the targets of chromosomal translocations in human alveolar rhabdomyosarcoma (i.e., a type of muscle cancer) (FOXO1) and acute leukemia (FOXO3 and FOXO4) . In these translocations, the encoded fusion proteins lack the FOXO DNA-binding domain, consistent with a loss of function. In addition, deletions of all three FoxO genes in the mouse result in the development of lymphoblastic thymic lymphomas and fatal hemagiomas that can progress to angiosarcomas (Paik et al., 2007) . Collectively, these data suggest that PI3K/AKT/ mTOR signaling contributes to tumor formation, in part, by inhibiting the activity of the FOXOs' tumor suppressors. In this issue of Cell, Sykes et al. (2011) Using a mouse model that mimics AMLs containing a translocation between chromosomes 9 and 11 (i.e., t(9;11)) which results in a fusion between the mixedlineage leukemia gene (MLL) and the AF9 gene, Sykes et al. demonstrate that the leukemia-initiating cells have attenuated AKT activation in response to growth factor stimulation. Moreover, forced activation of AKT in the leukemia-initiating cells leads to decreased growth, cellular differentiation, and apoptosis. As predicted, the decreased AKT activity in leukemia-initiating cells is associated with an increase in nuclear FOXOs and a transcriptional profile that is consistent with FOXO activation. Remarkably, conditional deletion of Foxo1, Foxo3, and Foxo4 in the MLL-AF9 model decreases colony forming ability, promotes myeloid differentiation, and decreases levels of LIC. These effects translate into a decrease in leukemic burden in vivo. Importantly, Sykes et al. then extend these observations to a subset of human AML cell lines and primary leukemias, including some that lack a MLL rearrangement. These data suggest that increased FOXO activity is required to maintain the immature state of leukemiainitiating cells by directly preventing their differentiation and apoptosis (Figure 1 ).
Another interesting finding comes when Sykes and colleagues analyze the leukemia cells that persist after deletion of FOXOs (i.e., cells resistant to the antileukemic activity of depleting FOXOs). In these cells, reduced FOXO activity induces activation of the JNK/cJUN pathway (Figure 1 ). Treating these cells with an inhibitor of JNK kinase leads to a decrease in cell growth, suggesting that JNK activity may partially mitigate the antileukemic activity of depleting FOXOs. This is consistent with data suggesting that JNK activation increases nuclear levels of FOXOs (Greer and Brunet, 2005) , although other pathways downstream of activated JNK may also come into play. An interesting practical implication of these data is that inhibition of the JNK pathway may have a therapeutic benefit in a subset of AMLs.
Although these data run counter to the established function of FOXOs as tumor suppressor, FOXOs' role in maintaining normal hematopoietic stem cells (HSC) provides some insights into what may be occurring in leukemia-initiating cells. Loss of FoxO1/3/4 in mice, despite inducing lymphoblastic thymic lymphomas, leads to a decrease in the levels of longterm HSCs, partially because of a loss of their quiescent state and an increase in apoptosis . FoxO3 activity appears critical for maintaining the self-renewal activity of HSCs (Miyamoto et al., 2007) . Similarly, loss of Pten or constitutive activation of AKT, although inducing leukemia, also leads to a depletion of normal HSCs (Yilmaz et al., 2006; Kharas et al., 2010; Lee et al., 2010) . In contrast to their effects on normal HSCs, both Pten loss and AKT activation induce an expansion of leukemia-initiating cells, the opposite of what is seen with the deletion of FoxOs. However, it is important to remember that, despite a dependence of some AMLs on FOXO activity, lymphoblastic thymic lymphoma develop in the absence of FoxOs in mice, and in human AML, almost 50% of cases have evidence of activated AKT, resulting in a decrease in FOXO activity. Thus, not all leukemia-initiating cells depend on FOXO activity to expand.
So how do we reconcile the disparate activities observed in normal and leukemic cells, as well as the contrasting activities of different members of the PI3K/ AKT/mTOR/FOXO pathway? First, it is important to remember that PI3K/AKT/ mTOR is not a simple linear pathway that culminates in the inhibition of FOXOs. Activation of the pathway at different points launches profoundly different downstream signals. Second, signaling through these pathways depends on the context and can vary not only between lineages, but also within a given lineage, depending on a cell's stage of development and differentiation. Consistent with these observations, loss of Pten leads to a high frequency of AML, whereas constitutive activation of AKT or loss of FoxO1/3/4 primarily leads to T cell lymphomas instead of AML.
Even with these caveats, we are left with more questions than answers. For instance, what pathways control a cell's response to the activation of PI3K/AKT or loss of FOXOs, and what dictates a common effect in normal HSCs but markedly different effects in leukemia-initiating cells? Also, do cooperating oncogenic mutations allow some leukemias to bypass the requirement for FOXO activity, and will inhibition of JNK activity in leukemias with reduced FOXO activity offer tangible therapeutic benefits in patients? Clearly, additional studies on the PI3K/ AKT/mTOR/FOXO pathway in normal and leukemic HSCs are necessary. It will also be important to accurately define the mutational status and functional activity of the individual components of this pathway in leukemias and to correlate these with a patient's response to therapy. Only once these types of data are in hand can we then develop a rational approach to target this pathway in leukemia and other cancers. The transcription factors FOXO1, FOXO3, and FOXO4 (i.e., ''the FOXOs'') induce cell-cycle arrest and apoptosis and contribute to the detoxification of reactive oxygen species (ROS). Through these pathways, FOXOs play a tumor suppressor role in a variety of cancers. Oncogenic signaling through the PI3K/AKT/ mTOR pathway inhibits the tumor suppressor activity of the FOXOs by AKT-mediated phosphorylation, resulting in their exclusion from the nucleus and degradation. In contrast to cancer cells, normal hematopoietic stem cells (HSCs) require FOXOs for their maintenance. Counter to their tumor suppressor role, the FOXOs are also required to maintain leukemia-initiating cells (LIC) in a subset of acute myeloid leukemias (Sykes et al., 2011) . Moreover, loss of FOXOs in LIC induces an increase in the activity of the JNK kinase, which counters the consequences of disrupting FOXO. This, in part, results from a positive effect of JNK on FOXO nuclear localization, although the exact mechanisms through which JNK induces FOXO nuclear localization remain incompletely defined.
